News | Cath Lab | April 17, 2017

Study Finds Significant Variability in Doctors' Angioplasty Death Rates

Judging doctors on mortality data may not give the full picture

Study Finds Significant Variability in Doctors Angioplasty Death Rates

April 17, 2017 — Some doctors have higher or lower than expected death rates from coronary angioplasty procedures, also known as percutaneous coronary intervention (PCI). However, doctors should not be judged solely on the rate of patients who die from the procedure, as the rate is highly variable over time, according to a recent study in JACC: Cardiovascular Interventions

PCI is a nonsurgical procedure that improves blood flow to the heart. It requires cardiac catheterization, which is the insertion of a catheter tube and injection of contrast dye into the coronary arteries. Doctors use PCI to open coronary arteries that are narrowed or blocked by the buildup of atherosclerotic plaque. PCI may be used to relieve symptoms of coronary heart disease or to reduce heart damage during or after a heart attack.

The new study analyzed data from the National Cardiovascular Data Registry CathPCI Registry to determine how many physicians had mortality rates outside the expected norm. The study included 3,760 doctors who performed 2,343,693 PCI procedures. The researchers adjusted for a number of factors, including how sick patients were.

The researchers found a small but significant number of doctors (6.5 percent) with mortality rates above what would be expected, as well as a small but significant number (4.1 percent) with mortality rates below what would be expected.

PCI mortality rates for individual doctors may be useful for both doctors and hospitals to assess and monitor their care and see where they need improvement, said Jacob Doll, M.D., a cardiologist at the University of Washington in Seattle and lead author of the study. “It could drive hospitals and doctors to further improve the safety of a procedure that’s already low-risk. However, I don’t see this measure as ready for widespread use as a publicly reported measure or to influence payment.”

A limitation with assessing mortality rates is that it is rare for patients to die from PCI — for every 100 procedures, only slightly more than 1 percent of patients die, and for elective PCI, death is very rare.

“Any given doctor may have only one or two deaths a year — some years just by chance you may have two or four, which seems like a lot, and the next year, you may have none. This may be further confounded by the low number of deaths that can be ascribed to the procedure, and makes it challenging to know whether these differences are actually due to the care received,” Doll said.

A number of factors affect a physician’s PCI mortality rate, Doll said. 

Because procedures performed on sicker patients often have higher mortality rates, Doll and colleagues took this into account, by using what is called a risk standardized mortality rate (RSMR).

“This helps us interpret the results to determine who really has a higher-than-expected morality rate, and who has a higher actual mortality rate because they take care of sicker patients,” he said.

In an editorial accompanying the study, Michael McDaniel, M.D., an assistant professor of medicine at Emory University School of Medicine in Atlanta, said that doctors concerned about their mortality rate being reported publicly may avoid treating the highest-risk patients.

 

Related NCDR CathPCI Registry articles:

• Radial Access, Same-Day Cardiac Procedure Could Save $300 Million Annually

• New Report Highlights National Trends in Heart Disease Treatments

• Better Prognosis for Some PCI Patients When Operators Perform More Procedures
 

 

For more information: www.interventions.onlinejacc.org

Related Content

New Multi-Center Research Effort to Focus on Early Life Origins of Heart Health
News | Congenital Heart| June 23, 2017
Heart health in children will be the focus of three closely synergistic research projects and an integrated...
Sponsored Content | Videos | Angiography| June 22, 2017
Shimadzu Medical Systems hghlighted new features of its Trinias Interventional X-ray line at the America College of C
Pacemakers and Other Cardiac Devices Can Help Solve Forensic Cases
News | Pacemakers| June 20, 2017
Pacemakers and other cardiac devices can help solve forensic cases, according to a study presented at the European...
BioTrace Medical's Tempo Lead Shows Stability and Safety in Real-World Performance
News | Leads Implantable Devices| June 20, 2017
BioTrace Medical Inc. announced that the company’s Tempo Temporary Pacing Lead was featured in an oral presentation and...
BioImage-2 Study to Investigate Atherosclerotic Disease Progression
News | Cardiovascular Ultrasound| June 20, 2017
Mount Sinai Heart and BioImage-2 LLC recently announced the start of the BioImage-2 study investigating the progression...
Stroke2prevent Receives FDA 510(k) Clearance for A-View
Technology | Ultrasound Transesophageal echo (TEE)| June 20, 2017
June 20, 2017 — Dutch medical device company Stroke2prevent BV recently announced it has received U.S.
IABP recall for Maquet, Datascope intra-aortic balloon pump CS100 and CS300

The Datascope CS300 IABP console.

News | Hemodynamic Support Devices| June 20, 2017
June 20, 2017 — The U.S.
Sponsored Content | Videos | Cardiovascular Ultrasound| June 15, 2017
Madhav Swaminathan, M.D., FASC, FAHA, clinical director of cardiothoracic anesthesiology, at Duke Univer
radial access, transradial access trial using anticoagulants
News | Radial Access| June 15, 2017
June 15, 2017 — In patients undergoing t...
Overlay Init